Literature DB >> 28965634

Management of Hypersensitivity Reactions to Taxanes.

Matthieu Picard1.   

Abstract

Taxanes are an important class of antineoplastic agents used in the treatment of a wide variety of cancers. However, paclitaxel and docetaxel, which are the most commonly used taxanes, elicit immediate hypersensitivity reactions (HSRs) in 5% to 10% of patients. Almost all patients that experience these reactions can be safely re-exposed to taxanes either through desensitization or challenge. This article describes the clinical presentation, diagnosis, and management of HSRs to taxanes and discusses the different options for their safe readministration.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Allergy; Desensitization and challenge; Docetaxel; Hypersensitivity; Paclitaxel; Skin test; Taxane

Mesh:

Substances:

Year:  2017        PMID: 28965634     DOI: 10.1016/j.iac.2017.07.004

Source DB:  PubMed          Journal:  Immunol Allergy Clin North Am        ISSN: 0889-8561            Impact factor:   3.479


  12 in total

Review 1.  Nanodelivery systems and stabilized solid-drug nanoparticles for orally administered medicine: current landscape.

Authors:  Ali Kermanizadeh; Leagh G Powell; Vicki Stone; Peter Møller
Journal:  Int J Nanomedicine       Date:  2018-11-16

2.  Cutaneous Toxicity After Chemoradiotherapy and PD-L1 Inhibition in Two Patients with Esophageal Adenocarcinoma: More than Meets the Eye.

Authors:  Tom van den Ende; Stef P Menting; Carmen A Ambarus; Martijn G H van Oijen; Hanneke W M van Laarhoven
Journal:  Oncologist       Date:  2019-03-22

Review 3.  Premedication Protocols to Prevent Hypersensitivity Reactions to Chemotherapy: a Literature Review.

Authors:  Faisal ALMuhizi; Leticia De Las Vecillas Sanchez; Lucy Gilbert; Ana M Copaescu; Ghislaine A C Isabwe
Journal:  Clin Rev Allergy Immunol       Date:  2022-03-08       Impact factor: 8.667

4.  SPR064, a pro-drug of paclitaxel, has anti-tumorigenic effects in endometrial cancer cell lines and mouse models.

Authors:  Xiaoling Zhao; Weimin Kong; Katherine Tucker; Allison Staley; Yali Fan; Wenchuan Sun; Yajie Yin; Yu Huang; Ziwei Fang; Jiandong Wang; Somdutta Sen; Sundeep Dugar; Chunxiao Zhou; Victoria L Bae-Jump
Journal:  Am J Transl Res       Date:  2020-08-15       Impact factor: 4.060

5.  Adverse Event Profile for Nanoparticle Albumin-Bound Paclitaxel Compared With Solvent-Based Taxanes in Solid-Organ Tumors: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.

Authors:  Fei He; Jiaxuan Liu; Xin Shen; Zijing Wang; Qiao Li; Guohui Li
Journal:  Ann Pharmacother       Date:  2021-12-28       Impact factor: 3.463

6.  Dual drug-loaded nano-platform for targeted cancer therapy: toward clinical therapeutic efficacy of multifunctionality.

Authors:  Zhe Ma; Nan Li; Bing Zhang; YuYu Hui; Ying Zhang; Peng Lu; Jiaxin Pi; Zhidong Liu
Journal:  J Nanobiotechnology       Date:  2020-09-04       Impact factor: 10.435

7.  Optimization, Characterization and in vivo Evaluation of Paclitaxel-Loaded Folate-Conjugated Superparamagnetic Iron Oxide Nanoparticles.

Authors:  Gang Gui; Ziqi Fan; Yihuan Ning; Cancan Yuan; Baolin Zhang; Qin Xu
Journal:  Int J Nanomedicine       Date:  2021-03-19

8.  A randomized double-blind feasibility study comparing cetirizine and diphenhydramine in the prevention of paclitaxel-associated infusion-related reactions: the PREMED-F1 study.

Authors:  Johannie Beaucage-Charron; Laurence Gaudet; Sarah Lamothe; Cloé Pelletier; Anne-Sophie Pépin; Valérie Roy; Frédéric Charpentier; Marie Lordkipanidzé; Denis Projean; Philippe Bouchard; Matthieu Picard
Journal:  Support Care Cancer       Date:  2022-01-08       Impact factor: 3.359

9.  Nab-paclitaxel and atezolizumab for the treatment of PD-L1-positive, metastatic triple-negative breast cancer: review and future directions.

Authors:  Jodi A Kagihara; Michelle Andress; Jennifer R Diamond
Journal:  Expert Rev Precis Med Drug Dev       Date:  2020-02-20

10.  Dexamethasone enhances the lung metastasis of breast cancer via a PI3K-SGK1-CTGF pathway.

Authors:  Yujing Zhang; Gang Shi; Hantao Zhang; Qi Xiong; Fuyi Cheng; Huiling Wang; Jieyan Luo; Yong Zhang; Pengyi Shi; Jia Xu; Jiamei Fu; Na Chen; Lin Cheng; Yiming Li; Lei Dai; Yang Yang; Dechao Yu; Shuang Zhang; Hongxin Deng
Journal:  Oncogene       Date:  2021-07-16       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.